GILD

L'intérêt à découvert pour Gilead Sciences donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Gilead Sciences. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Gilead Sciences (NASDAQ:GILD) Stock, Rapport sur les intérêts à découvert

Gilead Sciences

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Gilead Sciences Inc

Gildan Activewear, Inc. Class A Sub. Vot. Common Stock

Gildan Activewear Inc

In the current session, the stock is trading at $90.38, after a 0.21% increase. Over the past month, Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock increased by 2.40%, and in the past year, by 21.04%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732540506_0.png" alt="Past Year Chart" />

<h3>Gilead Sciences P/E Compared to Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 94.75 in the Biotechnology industry, Gilead Sciences Inc. has a higher P/E ratio of 1002.11. Shareholders might be inclined to think that Gilead Sciences Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732540506_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

News

Intraday Update

Markets

Price Over Earnings Overview: Gilead Sciences

UBS analyst Colin Bristow maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Neutral and raises the price target from $70 to $96.

Price Target

Analyst Ratings

UBS Maintains Neutral on Gilead Sciences, Raises Price Target to $96

Mizuho analyst Salim Syed maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $90 to $100.

Mizuho Maintains Outperform on Gilead Sciences, Raises Price Target to $100

During the last three months, 26 analysts shared their evaluations of Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">12</td>
<td align="right">13</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $92.73, with a high estimate of $125.00 and a low estimate of $70.00. This current average has increased by 12.55% from the previous average price target of $82.39. 
<img src="https://www.benzinga.com/files/images/story/2024/1731945610_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Gilead Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$84.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Alexandria Hammond</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$110.00</td>
<td>-</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Buy</td>
<td>$125.00</td>
<td>-</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$97.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$102.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Brian Skorney</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$81.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$84.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Neutral</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$95.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$105.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$96.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$94.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Aaron Gal</td>
<td>Bernstein</td>
<td>Announces</td>
<td>Outperform</td>
<td>$105.00</td>
<td>-</td>
</tr>
<tr>
<td>Chris Schott</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$84.00</td>
<td>$76.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$75.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Joseph Catanzaro</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Gilead Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Gilead Sciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Gilead Sciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Gilead Sciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/GILD/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Gilead Sciences analyst ratings.</a>
<h2>All You Need to Know About Gilead Sciences</h2>
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
<h3>Gilead Sciences: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Gilead Sciences's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 7.02%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Gilead Sciences's net margin is impressive, surpassing industry averages. With a net margin of 16.61%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Gilead Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of 6.82%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Gilead Sciences's ROA stands out, surpassing industry averages. With an impressive ROA of 2.32%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Gilead Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.26.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

26 Analysts Assess Gilead Sciences: What You Need To Know

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Sector Perform and raises the price target from $81 to $84.

RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $84

WIIM

AMGN

IONS

VKTX

Shares of pharmaceutical and healthcare stocks are trading lower. The sector has been under pressure after president-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

On Friday, Gilead Sciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) revealed data from a two-and-a-half-year interim analysis from the ongoing Phase 3 ASSURE study evaluating the long-term <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42012386/gileads-livdelzi-seladelpar-demonstrated-a-sustained-efficacy-and-long-term-safety-profile-in-mana" rel="noreferrer noopener">efficacy and safety of Livdelzi</a>.
The study showed that 81% (30 out of 37) of participants with primary biliary cholangitis (PBC) treated with Livdelzi&nbsp;(seladelpar) achieved a composite biochemical response (CBR), demonstrating significant improvements in a key measures of PBC progression.
Additionally, 41% (15 out of 37) of participants achieved normalization of alkaline phosphatase (ALP) levels, a critical biomarker of liver function.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost" rel="noreferrer noopener">HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook</a>
Livdelzi continues to appear generally well tolerated, with no new safety signals or change in frequency of adverse events (AEs) with up to three years of exposure.
In August, the FDA granted accelerated approval for&nbsp;Gilead&#8217;s Livdelzi&nbsp;for primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA or as monotherapy in patients&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal" rel="noreferrer noopener">unable to tolerate UDCA</a>.
In addition to the ASSURE data, Gilead showcased findings from two oral presentations highlighting additional analyses from the Phase 3 RESPONSE trial:
<ul>
<li>At Month 12, the adjusted mean change from baseline in ALP for participants with cirrhosis on Livdelzi was -121.4 U/L (a decrease of approximately 35% from baseline) versus 23.2 U/L (an increase of approximately 6.6%) on placebo.</li>
<li>-134.8 U/L (down 43.5%) for Livdelzi versus -18.0 U/L (a decrease of approximately 5.8%) for placebo in participants without cirrhosis.</li>
<li>A secondary analysis of pruritus in RESPONSE showed that among participants with a numerical rating score (NRS) of ≥4 and NRS ≥7 at baseline, Livdelzi led to near resolution (NRS of 0 or 1) of itch at Month 12 in 26.5% and 18.8% of participants, respectively, versus 0% of participants on placebo.</li>
</ul>
Price Action: GILD stock is down 3.48% at $88.90 at last check Friday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/bonds/24/11/42003337/trumps-victory-spurs-50b-corporate-bond-surge-as-tax-cut-optimism-drives-borrowing-costs-to-25-year-low" target="_blank" rel="noreferrer noopener">Trump&#8217;s Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low</a></li>
</ul>

Biotech

Equities

Large Cap

Health Care

Movers

Trading Ideas

General

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

Gilead's Livdelzi (Seladelpar) Shows Sustained Efficacy And Long-Term Safety In Primary Biliary Cholangitis; 81% Achieve Biochemical Response By Month 30, 41% Reach ALP Normalization, And 27% Experience Near Resolution Of Itch In Phase 3 ASSURE Study

In the wake of Donald Trump&#8217;s recent election victory, companies are rushing to tap into the US bond market, taking advantage of favorable conditions. Firms such as Caterpillar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAT#NYSE">CAT</a>), Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), and Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) have collectively raised over $50 billion in the past week.
What Happened: The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows. Investors are optimistic about potential tax cuts boosting profits, leading to a decrease in corporate borrowing costs relative to U.S. Treasuries, <a href="https://www.ft.com/content/5f9eb247-2851-4da7-ac19-62761fb46d1d">reported</a> The Financial Times on Friday. The U.S. investment-grade bond spreads were at 0.8 percentage points late Thursday, nearing their lowest since 1998.
Banks have been quick to capitalize on these conditions, with significant activity in the financial sector. 
See Also: <a href="https://www.benzinga.com/news/24/11/41963694/amid-appointment-of-elon-musk-vivek-ramswamy-team-trump-now-reportedly-planning-to-overhaul-military-posts?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Amid Appointment Of Elon Musk, Vivek Ramaswamy, Team Trump Now Reportedly Planning To Overhaul Military Posts</a>
Why It Matters: The bond market has been experiencing heightened volatility, as evidenced by <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">the MOVE index</a> reaching its highest level in over a year ahead of the U.S. election. 
Following Trump&#8217;s election, bond yields have <a href="https://www.benzinga.com/markets/bonds/24/11/41887642/bond-etfs-slide-as-fed-cuts-clash-with-trumps-fiscal-agenda">continued to rise</a>, complicating the Federal Reserve&#8217;s efforts to ease borrowing costs. The 10-year Treasury yield reached 4.34%, influenced by speculation surrounding Trump&#8217;s fiscal agenda.
Trump&#8217;s reelection has had a profound impact on financial markets, with the <a href="https://www.benzinga.com/trading-ideas/24/11/41977313/will-trumps-election-win-push-sp-500-even-higher-in-final-weeks-of-2024-over-75-say">S&amp;P 500 Index</a> reaching new all-time highs since the election. This contrasts the volatility experienced by the emerging <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984852/trumps-red-wave-pushes-emerging-market-stocks-to-2-month-lows-volatility-expected-to-remain-elevated">market stocks dropping</a> to levels last seen in mid-September.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/24/11/41910180/exclusive-chris-christie-says-trump-will-remove-federal-restrictions-on-marijuana-find-sweet-spot-for-crypto-regulation?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">EXCLUSIVE: Chris Christie Says Trump Will Remove Federal Restrictions On Marijuana, Find &#8216;Sweet Spot&#8217; For&nbsp;Crypto Regulation (UPDATED)</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Bonds

Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low

Wolfe Research analyst Alexandria Hammond initiates coverage on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform rating and announces Price Target of $110.

Initiation

Wolfe Research Initiates Coverage On Gilead Sciences with Outperform Rating, Announces Price Target of $110

Citigroup analyst Geoff Meacham initiates coverage on Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Buy rating and announces Price Target of $125.

Citigroup Initiates Coverage On Gilead Sciences with Buy Rating, Announces Price Target of $125

Reported Earlier, Gilead Sciences Prices $3.5B In Senior Notes, Including $1B Each For 2035 And 2054 Maturities

<ul>
<li>Newly Presented Results, to be Published in The New England Journal of Medicine, Include Adherence and Pharmacokinetics Data; Data Underscore High Efficacy and Safety Profile of Lenacapavir Among Broad and Geographically Diverse Range of Individuals.</li>
<li>FDA Recently Granted Breakthrough Therapy Designation for Lenacapavir for PrEP; Gilead to Begin Regulatory Filings by End of 2024.</li>
<li>Gilead Spearheading Lenacapavir Access Strategies to Ensure Scientific Innovation Translates to Global Access and Real-World Impact</li>
</ul>

Gilead Sciences Presented The First In-depth Look At Full Results From Its Pivotal Phase 3 PURPOSE 2 Trial Of Twice-yearly Lenacapavir For HIV Prevention

Gilead Said Bicstar Study Shows Sustained Efficacy And Safety Of Biktarvy

The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve&#8217;s interest rate cuts in September. 
According to GlobalData, the top 20 global biopharmaceutical companies <a href="https://www.globaldata.com/media/business-fundamentals/top-20-global-biopharmaceutical-companies-witness-2-growth-in-market-capitalization-in-q3-2024-reveals-globaldata/#:~:text=As%20a%20result%2C%20the%20top,data%20analytics%20and%20research%20company.">saw</a> a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. 
This rebound highlights the industry&#8217;s potential for growth despite challenges earlier in the year.
Bristol-Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) led the market with the largest increase in capitalization, which surged by 24.6% to $105 billion. This was largely driven by advancements in its pipeline, notably the FDA&#8217;s approval of its antipsychotic drug, Cobenfy, for treating <a href="https://www.benzinga.com/general/biotech/24/09/41064867/schizophrenia-treatment-revolution-fda-approves-bristol-myers-squibb-cobenfy-as-new-class-of-trea">schizophrenia in September 2024</a>. 
Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41819570/hiv-drugmaker-gilead-reports-strongest-quarterly-performance-of-2024-analysts-boost">posted impressive growth</a>, rising 22.1% in market value, thanks to the accelerated FDA approval of Livdelzi, a treatment for <a href="https://www.benzinga.com/general/biotech/24/08/40394698/fda-approves-gileads-seladelpar-for-inflammatory-liver-disease-acquired-via-4b-cymabay-deal">primary biliary cholangitis</a>, as well as the approval of its antibody-drug conjugate, Trodelvy, for HR-/HER2- breast cancer in Japan.
Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) experienced a 19.2% jump in market capitalization, largely fueled by its <a href="https://www.benzinga.com/general/biotech/24/10/41541274/sanofi-earns-5b-q3-core-profit-on-strong-dupixent-and-vaccine-sales-raises-2024-forecast">flagship drug Dupixent</a>. The drug&#8217;s strong performance in the treatment of conditions such as asthma and atopic dermatitis, coupled with its recent EMA and FDA approvals for chronic obstructive pulmonary disease (COPD), further <a href="https://www.benzinga.com/general/biotech/24/09/41069388/fda-approves-regeneronsanofis-blockbuster-dupixent-for-smokers-lung-disease">boosted Sanofi&#8217;s standing</a>. 
Similarly, AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) saw a 15.2% increase in its market cap, driven by the continued success of its immunology drugs—Humira, Skyrizi, and Rinvoq—which together generated nearly $7 billion <a href="https://www.benzinga.com/general/biotech/24/07/39960414/abbvies-q2-earnings-beat-estimates-raises-annual-profit-on-strong-sales-from-newer-immunology-and">in Q2 2024 sales</a>.
Alnylam Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) joined the top 20 biopharmaceutical companies with a 14.9% rise in its market value, following its RNAi drug vutrisiran's positive results in treating ATTR <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">amyloidosis with cardiomyopathy</a>. 
Roche Holdings AG's (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) market capitalization grew by 13.8%, spurred by the FDA&#8217;s approval of two key products, Ocrevus Zunovo for multiple sclerosis and Tecentriq Hybreza for oncology indications, the latter being the only approved subcutaneous <a href="https://www.benzinga.com/general/biotech/24/08/40652720/alnylam-pharmaceuticals-stock-falls-after-detailed-vutrisiran-data-for-a-condition-with-stiff-hea">PD-L1 inhibitor available</a>.
On the downside, Wegovy maker Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) saw an 18.2% drop in its market cap after the FDA rejected its BLA filing for the once-<a href="https://www.benzinga.com/general/biotech/24/07/39732571/fda-rejects-novo-nordisks-weekly-insulin-requests-information-related-to-manufacturing-process-ty">weekly insulin icodec</a>.
Similarly, Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) reported a slight decline of 2.1%, though both companies retained their leadership in diabetes and <a href="https://www.benzinga.com/general/biotech/24/10/41622207/eli-lilly-q3-earnings-mounjaro-sales-more-than-double-takes-2-98-billion-hit-to-profit-cuts-annua">weight loss drugs</a>. 
Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) also faced a 8.2% fall in market value, largely due to disappointing sales of its HPV vaccine, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41693101/mercks-gardasil-shot-challenges-to-continue-analysts-optimistic-for-newly-approved-">Gardasil, in China</a>.
&nbsp;"The biopharmaceutical industry is poised for a recovery, fueled by multiple FDA approvals leading to a rebound in companies that have seen declines in market capitalization in previous quarters, such as Gilead Sciences and Bristol-Myers Squibb,&#8221; says GlobalData analyst.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41853302/adc-therapeutics-faces-competitive-oncology-market-but-analyst-sees-100-upside-heres-why">ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why</a></li>
</ul>
Image Via Shutterstock

ABBV

ALNY

RHHBY

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks

Maxim Group analyst Jason McCarthy downgrades Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) from Buy to Hold.

Downgrades

Maxim Group Downgrades Gilead Sciences to Hold

Truist Securities analyst Asthika Goonewardene maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Hold and raises the price target from $83 to $97.

Truist Securities Maintains Hold on Gilead Sciences, Raises Price Target to $97

Oppenheimer analyst Hartaj Singh maintains Gilead Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) with a Outperform and raises the price target from $95 to $105.

Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to $105

Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) stock is trading higher on Thursday after the company reported better-than-expected third-quarter financial results and raised its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41786284/gilead-sciences-announces-third-quarter-2024-financial-results" rel="noreferrer noopener">fiscal year 2024 guidance</a>.
On Wednesday after market, Gilead reported third-quarter adjusted EPS of $2.02, down from $2.29 a year ago, beating the consensus of $1.55.
The HIV drug maker reported sales of $7.55 billion, up 7% year over year, beating the consensus of $7 billion, primarily due to higher sales in HIV and Veklury&nbsp;(remdesivir), Oncology and Liver Disease.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41434127/gilead-sciencesmercks-investigational-once-weekly-hiv-combo-therapy-shows-sustained-virus-suppres" rel="noreferrer noopener">Gilead Sciences/Merck&#8217;s Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks</a>
HIV&nbsp;product sales increased 9% to $5.1 billion, with Biktarvy sales increased 13% to $3.5 billion. Descovy&nbsp;sales jumped 15% to $586 million.
The&nbsp;Liver Disease&nbsp;portfolio sales increased 4% to $733 million. Veklury&nbsp;sales increased 9% to $692 million.
&#8220;Gilead&#8217;s third-quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% year-over-year growth for Biktarvy,&#8221; said Daniel O&#8217;Day, Chairman and CEO.
Guidance: Gilead Sciences raised its fiscal year 2024 adjusted EPS guidance from $3.60 &#8211; $3.90 to $4.25 &#8211; $4.45 compared to the consensus of $3.81.
The company expects 2024 product sales of $27.8 billion &#8211; $28.1 billion compared to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40291958/analysts-cite-improved-investor-sentiment-for-gilead-but-warn-of-limited-growth-at-" rel="noreferrer noopener">prior guidance of</a> $27.1 billion &#8211; $27.5 billion.
Analysts&#8217; reaction:
<ul>
<li>Piper Sandler maintains Gilead Sciences with an Overweight, raising the price <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noreferrer noopener">target from $95 to $105</a>.</li>
<li>Barclays reaffirms Gilead with an Equal-Weight rating while boosting the price target from $84 to $95.</li>
<li>Wells Fargo maintains Gilead with an Overweight rating, raising the price target from $100 to $105.</li>
<li>Cantor Fitzgerald reiterates Gilead with a Neutral rating, increasing the price target from $70 to $80.</li>
<li>Goldman Sachs maintains Gilead&#8217;s Neutral rating, lifting the price target from $74 to $84.</li>
<li>RBC Capital maintains Gilead&#8217;s Sector Perform rating and boosts the price target from $75 to $81.</li>
<li>JP Morgan maintains Gilead with an Overweight rating, raising the price target from $100 to $105.</li>
<li>Baird maintains Gilead&#8217;s Neutral rating, increasing the price target from $80 to $95.</li>
</ul>
Price Action: GILD stock is up 5.94% at $97.14 at last check Thursday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41817807/elanco-animal-q3-earnings-profit-beat-new-products-and-stabilized-business-to-drive" target="_blank" rel="noreferrer noopener">Elanco Animal Q3 Earnings: Profit Beat, New Products And Stabilized Business To Drive 2025 Sales</a></li>
</ul>

Analyst Color

Earnings

Guidance

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook

After Wednesday&#8217;s &#8220;everything rally&#8221; spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting.
The Fed is widely expected to cut interest rates by 25 basis points, bringing them to a range of 4.5%-4.75%, following a previous 50-basis-point cut in September.
Yet, all eyes are on Fed Chair Jerome Powell&#8217;s comments at 2:30 p.m. ET regarding the potential for future rate hikes and his views on inflation risks. Concerns from the market center on the possibility of a policy U-turn driven by higher fiscal deficits and price pressures from trade tariffs under a Trump administration.
Tech stocks led gains, with the Nasdaq 100 extending its record-breaking levels, surpassing 21,000 points and eyeing a third consecutive positive session. The S&amp;P 500 and Dow Jones posted more modest gains, while the Russell 2000 paused after Wednesday&#8217;s 5.8% leap.
Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) remained a top performer among mega-cap stocks, bolstered by expectations of Elon Musk&#8216;s influence in the upcoming administration.
Treasury yields reversed a substantial portion of Wednesday's post-election increase, while the U.S. dollar dipped by 0.7%.
Metal commodities rebounded after Wednesday&#8217;s sharp losses, with gold rising 1.3%, silver up 2% and copper rallying over 4%.
Oil prices strengthened by 1%, with West Texas Intermediate trading around $72 per barrel.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 0.8%, reaching $76,000 to extend its record highs, while Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) outperformed with a gain of over 4%.
<h1 class="wp-block-heading">Thursday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,050.78</td>
<td>1.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,968.27</td>
<td>0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,748.20</td>
<td>0.0%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,389.10</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
</figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.7% to $594.84.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;stalled at $437.25.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.3% to $512.38.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.3% to $236.67.</li>
<li>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, rising 1.3%. The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) lagged, down 1.2%.</li>
</ul>
<h1 class="wp-block-heading">Thursday&#8217;s Stock Movers</h1>
Some relevant reactions to earnings reports are:
<ul>
<li>Qualcomm Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCOM#NASDAQ">QCOM</a>), up 0.1%, </li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), up 6.2%, </li>
<li>MercadoLibre Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>), down 16%, </li>
<li>APPLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>), up 43%, </li>
<li>McKesson Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), up 11%, </li>
<li>Take-Two Interactive Software Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>), up 6.3%, </li>
<li>Transdigm Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>), down 4.4%</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41814589/why-trumps-boost-to-treasury-yields-inflation-expectations-may-weaken-feds-efforts-">Why Trump&#8217;s Boost To Treasury Yields, Inflation Expectations May Weaken Fed&#8217;s Efforts To Cut Interest Rates</a></li>
</ul>
This image was created using artificial intelligence.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Macro Economic Events

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

$ETH

SPDR Dow Jones Industrial Average ETF Trust

MELI

QCOM

TSLA

TTWO

XLRE

Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?

Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)

AUCATZYL's Approval Positions Autolus Therapeutics Favorably In The CAR-T Market

Mizuho raised the firm's price target on Gilead (GILD) to $100 from $90 and keeps an Outperform rating on the shares. The analyst updated models in...

Gilead price target raised to $100 from $90 at Mizuho

In a regulatory filing on Wednesday, Hookipa Pharma (HOOK) announced that on November 18, the company approved a plan to continue to improve its co...

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

HQH: Declines Bring Potential Opportunity

UBS raised the firm's price target on Gilead (GILD) to $96 from $70 and keeps a Neutral rating on the shares. The firm increased HIV PrEP and Livde...

Gilead price target raised to $96 from $70 at UBS

Optimism over global healthcare sector rises: Jefferies

3 'Buy' stocks and 2 'Hold' stocks according to Oppenheimer

AbbVie: Upgrading To 'Strong Buy' After Pullback

Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC

ALHC

AUTL

AZNCF

BIIB

CLOV

HOOK

MGRC

MRNA

NVSEF

REGN

RXST

SNYNF

SPGI

TEVA

TEVJF

Press Releases

Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024

Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World

Gilead Sciences Announces Third Quarter 2024 Financial Results

Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic

Gilead Sciences to Present at Upcoming Investor Engagements

Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline

Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Prices $3.5 Billion of Senior Unsecured Notes

Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Comments

Gilead Sciences

Intérêt court

Gilead Sciences (NASDAQ:GILD) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL